We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Excess API in Manufacturing Earns Sunrise a Warning
Excess API in Manufacturing Earns Sunrise a Warning
February 2, 2010
Sunrise Pharmaceutical received a warning letter after manufacturing some of its products with excess active pharmaceutical ingredient (API) without justification in its batch records.